Literature DB >> 21666730

Vaccines: a moving target.

Michael Eisenstein.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21666730     DOI： 10.1038/474S16a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  4 in total

1.  Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.

Authors:  Sharon E Frey; Michael Houghton; Stephen Coates; Sergio Abrignani; David Chien; Domenico Rosa; Piero Pileri; Ranjit Ray; Adrian M Di Bisceglie; Paola Rinella; Heather Hill; Mark C Wolff; Viola Schultze; Jang H Han; Bruce Scharschmidt; Robert B Belshe
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

Review 2.  Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses.

Authors:  Michael Houghton
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

3.  Relation between viral fitness and immune escape within the hepatitis C virus protease.

Authors:  J Söderholm; G Ahlén; A Kaul; L Frelin; M Alheim; C Barnfield; P Liljeström; O Weiland; D R Milich; R Bartenschlager; M Sällberg
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

4.  Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission.

Authors:  Claire L Brimacombe; Joe Grove; Luke W Meredith; Ke Hu; Andrew J Syder; Maria Victoria Flores; Jennifer M Timpe; Sophie E Krieger; Thomas F Baumert; Timothy L Tellinghuisen; Flossie Wong-Staal; Peter Balfe; Jane A McKeating
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103
  4 in total
  7 in total

Review 1.  Cancer Prevention: Lessons Learned and Future Directions.

Authors:  Barbara K Dunn; Barnett S Kramer
Journal:  Trends Cancer       Date:  2016-12

2.  Global geographical overlap of aflatoxin and hepatitis C: controlling risk factors for liver cancer worldwide.

Authors:  D L Palliyaguru; F Wu
Journal:  Food Addit Contam Part A Chem Anal Control Expo Risk Assess       Date:  2013-01-02

3.  Association of C-type lectin 18 levels with extrahepatic manifestations in chronic HCV infection.

Authors:  Tsai-Ling Liao; Ya-Lang Huang; Yi-Ming Chen; Hsiu-Chin Lee; Der-Yuan Chen; Shie-Liang Hsieh
Journal:  Sci Rep       Date:  2018-11-23       Impact factor: 4.379

Review 4.  Current trends in targeted therapy for drug-resistant infections.

Authors:  Leila Rahbarnia; Safar Farajnia; Behrooz Naghili; Vahideh Ahmadzadeh; Kamal Veisi; Roghayyeh Baghban; Sayna Toraby
Journal:  Appl Microbiol Biotechnol       Date:  2019-08-14       Impact factor: 4.813

5.  A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.

Authors:  Anne Fournillier; Lars Frelin; Emilie Jacquier; Gustaf Ahlén; Anette Brass; Estelle Gerossier; Fredrik Holmström; Kate E Broderick; Niranjan Y Sardesai; Jean-Yves Bonnefoy; Geneviève Inchauspé; Matti Sällberg
Journal:  J Infect Dis       Date:  2013-06-17       Impact factor: 5.226

6.  Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination.

Authors:  G Ahlén; F Holmström; A Gibbs; M Alheim; L Frelin
Journal:  Gene Ther       Date:  2014-05-29       Impact factor: 5.250

7.  A Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3/4 Protein Exhibits Immunogenic Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine.

Authors:  Fengqin Zhu; Tian Chen; Yeqiong Zhang; Haixia Sun; Hong Cao; Jianxi Lu; Linshan Zhao; Gang Li
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.